ChloroquineV1, Main, Exploration, bibRecord, 003366

d-penicillamine: Chemistry and clinical use in rheumatic disease

Identifieur interne : 003366 ( Main/Exploration ); précédent : 003365; suivant : 003367

d-penicillamine: Chemistry and clinical use in rheumatic disease

Auteurs : Helen E. Howard-Lock [Canada] ; Colin J. L. Lock [Canada] ; Amirudin Mewa [Canada] ; Walter F. Kean [Canada]

Source :

Seminars in Arthritis and Rheumatism [ 0049-0172 ] ; 1986.

RBID : ISTEX:8D8D2F7DD3C19ACFBCF64FACBB8F16896B1CAF2E

English descriptors

Teeft :
- Abnormality, Adverse effects, Adverse reactions, Amino, Amino acids, Ankylosing spondylitis, Arthritis, Arthritis rheum, Articular index, Aurothiomalate, Case reports, Chelate, Chelation, Chem, Clin, Control group, Crystal structure, Cystinuria, Discontinuation, Disodium aurothiomalate, Disulfide, Dos, Early rash, Free radicals, Gold therapy, Gravis, Grip strength, Higher incidence, Inorganic medicine, Intern, Jaffe, Kean, Lancet, Leukocyte count, Long term, Lower doses, Maintenance dose, Materials research, Metal complexes, Molecular structure, Myasthenia, Myasthenia gravis, Myochrysine, Nephrotic syndrome, Other hand, Palindromic rheumatism, Penicillamine, Penicillamine therapy, Penicillamine treatment, Penicillin, Placebo, Platelet, Platelet count, Proteinuria, Randomized, Rash, Renal, Rheum, Rheumatoid, Rheumatoid arthritis, Rheumatoid disease, Rheumatoid factor, Rheumatol, Scleroderma, Sclerosis, Side effects, Significant improvement, Skin rash, Superoxide, Superoxide dismutase, Suppl, Syndrome, Synthetische versuche, Thiazolidine, Thiazolidine formation, Toxicity, Treatment group, Wilson disease.

Abstract

Abstract: The discovery of d-penicillamine and its uses in medicine are reviewed. Chemical-physical properties are discussed, and the molecular structure of d-penicillamine and several of its reaction products are illustrated. Examples of its three main types of biochemical reactions—sulfhydryl-disulfide exchange, thiazolidine formation, and metal chelation are included. Trials of d-penicillamine in RA patients are reviewed critically. The administration of the drug is discussed in detail, including dosages, clinical and laboratory responses, patterns of adverse side effects or toxicity, drug-induced autoimmune diseases, indications and contraindications, and the monitoring and management of patients.

Url:

https://api.istex.fr/ark:/67375/6H6-17G9LFGV-4/fulltext.pdf

DOI: 10.1016/0049-0172(86)90022-3

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Istex, to step Corpus: 001617
to stream Istex, to step Curation: 001617
to stream Istex, to step Checkpoint: 002121
to stream Main, to step Merge: 003439
to stream Main, to step Curation: 003366

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>d-penicillamine: Chemistry and clinical use in rheumatic disease</title>
<author><name sortKey="Howard Lock, Helen E" sort="Howard Lock, Helen E" uniqKey="Howard Lock H" first="Helen E." last="Howard-Lock">Helen E. Howard-Lock</name>
</author>
<author><name sortKey="Lock, Colin J L" sort="Lock, Colin J L" uniqKey="Lock C" first="Colin J. L." last="Lock">Colin J. L. Lock</name>
</author>
<author><name sortKey="Mewa, Amirudin" sort="Mewa, Amirudin" uniqKey="Mewa A" first="Amirudin" last="Mewa">Amirudin Mewa</name>
</author>
<author><name sortKey="Kean, Walter F" sort="Kean, Walter F" uniqKey="Kean W" first="Walter F." last="Kean">Walter F. Kean</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:8D8D2F7DD3C19ACFBCF64FACBB8F16896B1CAF2E</idno>
<date when="1986" year="1986">1986</date>
<idno type="doi">10.1016/0049-0172(86)90022-3</idno>
<idno type="url">https://api.istex.fr/ark:/67375/6H6-17G9LFGV-4/fulltext.pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001617</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001617</idno>
<idno type="wicri:Area/Istex/Curation">001617</idno>
<idno type="wicri:Area/Istex/Checkpoint">002121</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">002121</idno>
<idno type="wicri:doubleKey">0049-0172:1986:Howard Lock H:d:penicillamine:chemistry</idno>
<idno type="wicri:Area/Main/Merge">003439</idno>
<idno type="wicri:Area/Main/Curation">003366</idno>
<idno type="wicri:Area/Main/Exploration">003366</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a">d-penicillamine: Chemistry and clinical use in rheumatic disease</title>
<author><name sortKey="Howard Lock, Helen E" sort="Howard Lock, Helen E" uniqKey="Howard Lock H" first="Helen E." last="Howard-Lock">Helen E. Howard-Lock</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Laboratories for Inorganic Medicine, Institute for Materials Research</wicri:regionArea>
<wicri:noRegion>Institute for Materials Research</wicri:noRegion>
</affiliation>
<affiliation wicri:level="4"><country xml:lang="fr">Canada</country>
<wicri:regionArea>1From the Laboratories for Inorganic Medicine, Institute for Materials Research, and the Rheumatic Diseases Unit, McMaster University, Hamilton, Ontario</wicri:regionArea>
<orgName type="university">Université McMaster</orgName>
<placeName><settlement type="city">Hamilton (Ontario)</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lock, Colin J L" sort="Lock, Colin J L" uniqKey="Lock C" first="Colin J. L." last="Lock">Colin J. L. Lock</name>
<affiliation wicri:level="4"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Address reprint requests to Helen E. Howard-Lock, PhD, Laboratories for Inorganic Medicine, Institute for Materials Research, McMaster University, Hamilton, Ontario L8S 4M1</wicri:regionArea>
<orgName type="university">Université McMaster</orgName>
<placeName><settlement type="city">Hamilton (Ontario)</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Laboratories for Inorganic Medicine, Institute for Materials Research</wicri:regionArea>
<wicri:noRegion>Institute for Materials Research</wicri:noRegion>
</affiliation>
<affiliation wicri:level="4"><country xml:lang="fr">Canada</country>
<wicri:regionArea>1From the Laboratories for Inorganic Medicine, Institute for Materials Research, and the Rheumatic Diseases Unit, McMaster University, Hamilton, Ontario</wicri:regionArea>
<orgName type="university">Université McMaster</orgName>
<placeName><settlement type="city">Hamilton (Ontario)</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Mewa, Amirudin" sort="Mewa, Amirudin" uniqKey="Mewa A" first="Amirudin" last="Mewa">Amirudin Mewa</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Medicine</wicri:regionArea>
</affiliation>
<affiliation wicri:level="4"><country xml:lang="fr">Canada</country>
<wicri:regionArea>1From the Laboratories for Inorganic Medicine, Institute for Materials Research, and the Rheumatic Diseases Unit, McMaster University, Hamilton, Ontario</wicri:regionArea>
<orgName type="university">Université McMaster</orgName>
<placeName><settlement type="city">Hamilton (Ontario)</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kean, Walter F" sort="Kean, Walter F" uniqKey="Kean W" first="Walter F." last="Kean">Walter F. Kean</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Medicine, Associate Professor of Medicine</wicri:regionArea>
<wicri:noRegion>Associate Professor of Medicine</wicri:noRegion>
</affiliation>
<affiliation wicri:level="4"><country xml:lang="fr">Canada</country>
<wicri:regionArea>1From the Laboratories for Inorganic Medicine, Institute for Materials Research, and the Rheumatic Diseases Unit, McMaster University, Hamilton, Ontario</wicri:regionArea>
<orgName type="university">Université McMaster</orgName>
<placeName><settlement type="city">Hamilton (Ontario)</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Seminars in Arthritis and Rheumatism</title>
<title level="j" type="abbrev">YSARH</title>
<idno type="ISSN">0049-0172</idno>
<imprint><publisher>ELSEVIER</publisher>
<date type="published" when="1986">1986</date>
<biblScope unit="volume">15</biblScope>
<biblScope unit="issue">4</biblScope>
<biblScope unit="page" from="261">261</biblScope>
<biblScope unit="page" to="281">281</biblScope>
</imprint>
<idno type="ISSN">0049-0172</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0049-0172</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Abnormality</term>
<term>Adverse effects</term>
<term>Adverse reactions</term>
<term>Amino</term>
<term>Amino acids</term>
<term>Ankylosing spondylitis</term>
<term>Arthritis</term>
<term>Arthritis rheum</term>
<term>Articular index</term>
<term>Aurothiomalate</term>
<term>Case reports</term>
<term>Chelate</term>
<term>Chelation</term>
<term>Chem</term>
<term>Clin</term>
<term>Control group</term>
<term>Crystal structure</term>
<term>Cystinuria</term>
<term>Discontinuation</term>
<term>Disodium aurothiomalate</term>
<term>Disulfide</term>
<term>Dos</term>
<term>Early rash</term>
<term>Free radicals</term>
<term>Gold therapy</term>
<term>Gravis</term>
<term>Grip strength</term>
<term>Higher incidence</term>
<term>Inorganic medicine</term>
<term>Intern</term>
<term>Jaffe</term>
<term>Kean</term>
<term>Lancet</term>
<term>Leukocyte count</term>
<term>Long term</term>
<term>Lower doses</term>
<term>Maintenance dose</term>
<term>Materials research</term>
<term>Metal complexes</term>
<term>Molecular structure</term>
<term>Myasthenia</term>
<term>Myasthenia gravis</term>
<term>Myochrysine</term>
<term>Nephrotic syndrome</term>
<term>Other hand</term>
<term>Palindromic rheumatism</term>
<term>Penicillamine</term>
<term>Penicillamine therapy</term>
<term>Penicillamine treatment</term>
<term>Penicillin</term>
<term>Placebo</term>
<term>Platelet</term>
<term>Platelet count</term>
<term>Proteinuria</term>
<term>Randomized</term>
<term>Rash</term>
<term>Renal</term>
<term>Rheum</term>
<term>Rheumatoid</term>
<term>Rheumatoid arthritis</term>
<term>Rheumatoid disease</term>
<term>Rheumatoid factor</term>
<term>Rheumatol</term>
<term>Scleroderma</term>
<term>Sclerosis</term>
<term>Side effects</term>
<term>Significant improvement</term>
<term>Skin rash</term>
<term>Superoxide</term>
<term>Superoxide dismutase</term>
<term>Suppl</term>
<term>Syndrome</term>
<term>Synthetische versuche</term>
<term>Thiazolidine</term>
<term>Thiazolidine formation</term>
<term>Toxicity</term>
<term>Treatment group</term>
<term>Wilson disease</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Abstract: The discovery of d-penicillamine and its uses in medicine are reviewed. Chemical-physical properties are discussed, and the molecular structure of d-penicillamine and several of its reaction products are illustrated. Examples of its three main types of biochemical reactions—sulfhydryl-disulfide exchange, thiazolidine formation, and metal chelation are included. Trials of d-penicillamine in RA patients are reviewed critically. The administration of the drug is discussed in detail, including dosages, clinical and laboratory responses, patterns of adverse side effects or toxicity, drug-induced autoimmune diseases, indications and contraindications, and the monitoring and management of patients.</div>
</front>
</TEI>
<affiliations><list><country><li>Canada</li>
</country>
<region><li>Ontario</li>
</region>
<settlement><li>Hamilton (Ontario)</li>
</settlement>
<orgName><li>Université McMaster</li>
</orgName>
</list>
<tree><country name="Canada"><noRegion><name sortKey="Howard Lock, Helen E" sort="Howard Lock, Helen E" uniqKey="Howard Lock H" first="Helen E." last="Howard-Lock">Helen E. Howard-Lock</name>
</noRegion>
<name sortKey="Howard Lock, Helen E" sort="Howard Lock, Helen E" uniqKey="Howard Lock H" first="Helen E." last="Howard-Lock">Helen E. Howard-Lock</name>
<name sortKey="Kean, Walter F" sort="Kean, Walter F" uniqKey="Kean W" first="Walter F." last="Kean">Walter F. Kean</name>
<name sortKey="Kean, Walter F" sort="Kean, Walter F" uniqKey="Kean W" first="Walter F." last="Kean">Walter F. Kean</name>
<name sortKey="Lock, Colin J L" sort="Lock, Colin J L" uniqKey="Lock C" first="Colin J. L." last="Lock">Colin J. L. Lock</name>
<name sortKey="Lock, Colin J L" sort="Lock, Colin J L" uniqKey="Lock C" first="Colin J. L." last="Lock">Colin J. L. Lock</name>
<name sortKey="Lock, Colin J L" sort="Lock, Colin J L" uniqKey="Lock C" first="Colin J. L." last="Lock">Colin J. L. Lock</name>
<name sortKey="Mewa, Amirudin" sort="Mewa, Amirudin" uniqKey="Mewa A" first="Amirudin" last="Mewa">Amirudin Mewa</name>
<name sortKey="Mewa, Amirudin" sort="Mewa, Amirudin" uniqKey="Mewa A" first="Amirudin" last="Mewa">Amirudin Mewa</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003366 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003366 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    ChloroquineV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:8D8D2F7DD3C19ACFBCF64FACBB8F16896B1CAF2E
   |texte=   d-penicillamine: Chemistry and clinical use in rheumatic disease
}}

This area was generated with Dilib version V0.6.33.
Data generation: Wed Mar 25 22:43:59 2020. Site generation: Sun Jan 31 12:44:45 2021

	Serveur d'exploration Chloroquine
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration Chloroquine

d-penicillamine: Chemistry and clinical use in rheumatic disease

d-penicillamine: Chemistry and clinical use in rheumatic disease

Source :

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri